keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunotherapy

keyword
https://www.readbyqxmd.com/read/28217432/cost-effectiveness-of-grass-pollen-scit-compared-with-slit-and-symptomatic-treatment
#1
Thomas Reinhold, Bernd Brüggenjürgen
BACKGROUND: Whereas specific immunotherapy (SIT) has already been shown to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment, only a small number of investigations have compared sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches. This analysis discusses the cost-effectiveness of SCIT compared with SLIT and a symptomatic treatment modality. At the same time, particular attention is paid to preparation-specific characteristics...
2017: Allergo Journal International
https://www.readbyqxmd.com/read/28213675/-adherence-in-specific-immunotherapy
#2
REVIEW
M-L Lemberg, M-J Joisten, R Mösges
Allergies are steadily gaining in importance in the Western world. For over one hundred years, immunology has been the only causal treatment. Specific immunotherapy (SIT) aims at the cure of allergy or at least freedom from allergy symptoms. In association with this, adherence poses a complex problem. Both treatment applications commonly used in Germany-sublingual and subcutaneous immunotherapy-show poor persistence on the part of the patients. In most cases, SIT is not carried out to the end of the recommended duration and instead is discontinued prematurely...
February 17, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28212561/the-tlr7-agonist-imiquimod-induces-anti-cancer-effects-via-autophagic-cell-death-and-enhances-anti-tumoral-and-systemic-immunity-during-radiotherapy-for-melanoma
#3
Jeong Hyun Cho, Hyo-Ji Lee, Hyun-Jeong Ko, Byung-Il Yoon, Jongseon Choe, Keun-Cheol Kim, Tae-Wook Hahn, Jeong A Han, Sun Shim Choi, Young Mee Jung, Kee-Ho Lee, Yun-Sil Lee, Yu-Jin Jung
Toll-like receptor (TLR) ligands are strongly considered immune-adjuvants for cancer immunotherapy and have been shown to exert direct anti-cancer effects. This study was performed to evaluate the synergistic anti-cancer and anti-metastatic effects of the TLR7 agonist imiquimod (IMQ) during radiotherapy for melanoma. The pretreatment of B16F10 or B16F1 cells with IMQ combined with γ-ionizing radiation (IR) led to enhanced cell death via autophagy, as demonstrated by increased expression levels of autophagy-related genes, and an increased number of autophagosomes in both cell lines...
February 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28196255/effect-of-2-years-of-treatment-with-sublingual-grass-pollen-immunotherapy-on-nasal-response-to-allergen-challenge-at-3-years-among-patients-with-moderate-to-severe-seasonal-allergic-rhinitis-the-grass-randomized-clinical-trial
#4
Guy W Scadding, Moises A Calderon, Mohamed H Shamji, Aarif O Eifan, Martin Penagos, Florentina Dumitru, Michelle L Sever, Henry T Bahnson, Kaitie Lawson, Kristina M Harris, Audrey G Plough, Joy Laurienzo Panza, Tielin Qin, Noha Lim, Nadia K Tchao, Alkis Togias, Stephen R Durham
Importance: Sublingual immunotherapy and subcutaneous immunotherapy are effective in seasonal allergic rhinitis. Three years of continuous treatment with subcutaneous immunotherapy and sublingual immunotherapy has been shown to improve symptoms for at least 2 years following discontinuation of treatment. Objective: To assess whether 2 years of treatment with grass pollen sublingual immunotherapy, compared with placebo, provides improved nasal response to allergen challenge at 3-year follow-up...
February 14, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28194483/-placebo-effect-in-clinical-trials-with-allergen-specific-immunotherapy-with-inhalant-allergens
#5
B Wedi, D Wieczorek, A Kapp
Placebo effects play an important role in the treatment of allergic diseases. Therefore, in this study, we analysed the described effects of placebo in all double-blind placebo-controlled clinical trials of allergen-specific immunotherapy (ASIT) with inhalant allergens (birch, grass, house dust mites) listed in the tables (updated July 2016) attached to the German S2k guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. The most common placebo consisted of verum without allergen, but when the subcutaneous route was used, histamine was sometimes added...
February 13, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28188713/-safety-of-subcutaneous-immunotherapy-with-tyrosine-adsorbed-house-dust-mite-extracts-in-patients-with-allergic-disease
#6
Mónica María Molina-Sáenz, Ana María Villa-Arango, Ricardo Cardona-Villa
BACKGROUND: In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions. OBJECTIVE: To evaluate systemic adverse reactions in patients with atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts. METHODS: Retrospective study of the 2010-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system...
January 2017: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://www.readbyqxmd.com/read/28188670/a-randomized-phase-ii-trial-of-personalized-peptide-vaccine-with-low-dose-cyclophosphamide-in-biliary-tract-cancer
#7
Takahisa Shirahama, Daisuke Muroya, Satoko Matsueda, Akira Yamada, Shigeki Shichijo, Masayasu Naito, Takuto Yamashita, Shinjiro Sakamoto, Koji Okuda, Kyogo Itoh, Tetsuro Sasada, Shigeru Yutani
Since the prognosis of advanced biliary tract cancer (aBTC) still remains very poor, new therapeutic approaches, including immunotherapies, need to be developed. In the current study, we conducted an open-label randomized phase II study to test whether low dose cyclophosphamide (CPA) could improve antigen-specific immune responses and clinical efficacy of personalized peptide vaccination (PPV) in 49 previously treated aBTC patients. Patients with aBTC refractory to at least one regimen of chemotherapies were randomly assigned to receive PPV with low dose CPA (100 mg/ day for 7 days before vaccination) (PPV/CPA, n=24) or PPV alone (n=25)...
February 11, 2017: Cancer Science
https://www.readbyqxmd.com/read/28162007/clinical-use-of-adjuvants-in-allergen-immunotherapy
#8
L Klimek, C B Schmidt-Weber, M F Kramer, M A Skinner, M D Heath
Introduction Allergen-specific Immunotherapy (AIT) is the only available treatment aimed to tackle the underlying causes of allergy. The active components of subcutaneous vaccines traditionally consist of natural or modified allergen extracts which can be combined with adjuvant platforms. In recent years new targets have been further developed in an attempt to raise the safety and efficacy profile of AIT. Areas Covered In this review, we discuss the desirable attributes of adjuvants and delivery systems from empiricism to rational design, for current and future clinical applications in AIT...
February 4, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28152201/biomarkers-for-monitoring-clinical-efficacy-of-allergen-immunotherapy-for-allergic-rhinoconjunctivitis-and-allergic-asthma-an-eaaci-position-paper
#9
M H Shamji, J H Kappen, M Akdis, E Jensen-Jarolim, E F Knol, J Kleine-Tebbe, B Bohle, A M Chaker, S J Till, R Valenta, L K Poulsen, M A Calderon, P Demoly, O Pfaar, L Jacobsen, S R Durham, C B Schmidt-Weber
Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma (1-12). AIT has disease modifying properties and confers long-term clinical benefit after cessation of treatment (6, 7, 13-17). AIT is routinely used in daily practice and can be administered either subcutaneously (SCIT) or sublingually (SLIT) (3-12). Although AIT is effective, the degree of remission strongly varies depending on the complex interaction between patient, allergy, symptomatology and vaccines used for AIT (3-9)...
February 2, 2017: Allergy
https://www.readbyqxmd.com/read/28141955/investigational-new-drugs-for-allergic-rhinitis
#10
Peter A Ricketti, Sultan Alandijani, Chen Hsing Lin, Thomas B Casale
Allergic rhinitis (AR) is a multifactorial disease characterized by paroxysmal symptoms of sneezing, rhinorrhea, postnasal drip and nasal congestion. For over a century, subcutaneous allergen immunotherapy (SCIT) has been recognized as the most effective therapy to date that may modify the underlying disease course and provide long-term benefits for individuals refractory to pharmacotherapy. However, over the past 25 years, there has been substantial growth in developing alternative therapies to traditional SCIT...
January 31, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28133873/the-future-of-immunotherapy-for-canine-atopic-dermatitis-a-review
#11
REVIEW
Douglas J DeBoer
Allergen specific immunotherapy (ASIT) is a foundation treatment for canine atopic dermatitis (CAD), though few critical studies have documented its effectiveness as a disease-modifying treatment in dogs. The mechanisms by which ASIT works in dogs have not been elucidated, although they are likely to parallel those known for humans. Current ASIT approaches in CAD focus on either subcutaneous or sublingual administration. Greater knowledge of major allergens in dogs, ideal dosage regimes and details of allergen admixture are likely to lead to better efficacy in CAD...
February 2017: Veterinary Dermatology
https://www.readbyqxmd.com/read/28124639/new-routes-of-allergen-immunotherapy
#12
Mitat Aricigil, Nuray Bayar Muluk, Engin Umut Sakarya, Emine Güven Sakalar, Mehmet Senturk, William R Reisacher, Cemal Cingi
OBJECTIVES: Allergen immunotherapy is the only cure for immunoglobulin E mediated type I respiratory allergies. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most common treatments. In this article, we reviewed new routes of allergen immunotherapy. METHODS: Data on alternative routes to allow intralymphatic immunotherapy (ILIT), epicutaneous immunotherapy (EPIT), local nasal immunotherapy (LNIT), oral immunotherapy (OIT), and oral mucosal immunotherapy (OMIT) were gathered from the literature and were discussed...
November 1, 2016: American Journal of Rhinology & Allergy
https://www.readbyqxmd.com/read/28115832/sublingual-versus-subcutaneous-immunotherapy-patient-adherence-at-a-large-german-allergy-center
#13
Marie-Luise Lemberg, Till Berk, Kija Shah-Hosseini, Elena-Manja Kasche, Ralph Mösges
BACKGROUND: Many placebo-controlled studies have demonstrated that allergen immunotherapy (AIT) is an effective therapy for treating allergies. Both commonly used routes, subcutaneous (SCIT) and sublingual immunotherapy (SLIT), require high patient adherence to be successful. In the literature, numbers describing adherence vary widely; this investigation compares these two routes of therapy directly. METHODS: All data were retrieved from the patient data management system of a center for dermatology, specific allergology, and environmental medicine in Germany...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28111220/prophylactic-active-immunization-with-a-novel-epitope-vaccine-improves-cognitive-ability-by-decreasing-amyloid-plaques-and-neuroinflammation-in-app-ps1-transgenic-mice
#14
Li Ding, Yuan Meng, Hui-Yi Zhang, Wen-Chao Yin, Yi Yan, Yun-Peng Cao
Both amyloid-β peptide (Aβ) deposition and neuroinflammation are considered to be early events that play pivotal roles in Alzheimer's disease (AD) pathogenesis and its associated cognitive impairment. Prophylactic anti-Aβ active immunotherapy is a promising therapeutic strategy for AD, if the Aβ-specific autoimmune responses to self T cell epitopes of Aβ can be avoided. This can be achieved by the use of antigen, which contains the B cell epitope of Aβ and excludes the Aβ-specific T cell epitope. In this study, we developed a novel peptide epitope vaccine, Aβ3-10-KLH, by coupling the B cell epitope Aβ3-10 to keyhole limpet hemocyanin (KLH) as the carrier protein, and subcutaneously injected it into 2...
January 19, 2017: Neuroscience Research
https://www.readbyqxmd.com/read/28074864/a-novel-monoclonal-antibody-targeting-coxsackie-virus-and-adenovirus-receptor-inhibits-tumor-growth-in-vivo
#15
Manabu Kawada, Hiroyuki Inoue, Masunori Kajikawa, Masahito Sugiura, Shuichi Sakamoto, Sakiko Urano, Chigusa Karasawa, Ihomi Usami, Mitsuru Futakuchi, Tohru Masuda
To create a new anti-tumor antibody, we conducted signal sequence trap by retrovirus-meditated expression method and identified coxsackie virus and adenovirus receptor (CXADR) as an appropriate target. We developed monoclonal antibodies against human CXADR and found that one antibody (6G10A) significantly inhibited the growth of subcutaneous as well as orthotopic xenografts of human prostate cancer cells in vivo. Furthermore, 6G10A also inhibited other cancer xenografts expressing CXADR, such as pancreatic and colorectal cancer cells...
January 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28070824/tolerability-of-an-immunologically-enhanced-subcutaneous-immunotherapy-preparation-in-patients-treated-with-concomitant-allergy-immunotherapy-a-non-interventional-observational-study
#16
Rainer Reiber, Hendrik Wolf, Jörg Schnitker, Eike Wüstenberg
BACKGROUND: For causal treatment by allergy immunotherapy (AIT) a single or few allergen products for the clinically most relevant allergens are applied to treat multiple allergies, but few data on the tolerability of multiple AIT applications are available. OBJECTIVE: The aim of our study was to investigate safety and tolerability in patients treated by subcutaneous immunotherapy (SCIT) and concomitant SCIT or sublingual immunotherapy (SLIT) products. METHODS: In a non-interventional, observational study in Germany treatment of patients with a primary SCIT and concomitant AIT (SCIT or SLIT) was documented during the first 4 months of treatment...
January 9, 2017: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/28065341/allergen-immunotherapy-for-a-teenager-with-seasonal-allergic-rhinitis-due-to-grass-pollen-subcutaneous-or-sublingual-route
#17
REVIEW
Harold S Nelson, Stephen R Durham
No abstract text is available yet for this article.
January 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28063043/subcutaneous-and-sublingual-immunotherapy-in-a-mouse-model-of-allergic-asthma
#18
Laura Hesse, Martijn C Nawijn
Allergic asthma, caused by inhaled allergens such as house dust mite or grass pollen, is characterized by reversible airway obstruction, associated with an eosinophilic inflammation of the airways, as well as airway hyper responsiveness and remodeling. The inhaled allergens trigger a type-2 inflammatory response with involvement of innate lymphoid cells (ILC2) and Th2 cells, resulting in high production of immunoglobulin E (IgE) antibodies. Consequently, renewed allergen exposure results in a classic allergic response with a distinct early and late phase, both resulting in bronchoconstriction and shortness of breath...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28057014/cocktail-treatment-with-egfr-specific-and-cd133-specific-chimeric-antigen-receptor-modified-t-cells-in-a-patient-with-advanced-cholangiocarcinoma
#19
Kai-Chao Feng, Ye-Lei Guo, Yang Liu, Han-Ren Dai, Yao Wang, Hai-Yan Lv, Jian-Hua Huang, Qing-Ming Yang, Wei-Dong Han
BACKGROUND: Cholangiocarcinoma (CCA) is one of the most fatal malignant tumors with increasing incidence, mortality, and insensitivity to traditional chemo-radiotherapy and targeted therapy. Chimeric antigen receptor-modified T cell (CART) immunotherapy represents a novel strategy for the management of many malignancies. However, the potential of CART therapy in treating advanced unresectable/metastatic CCA is uncharted so far. CASE PRESENTATION: In this case, a 52-year-old female who was diagnosed as advanced unresectable/metastatic CCA and resistant to the following chemotherapy and radiotherapy was treated with CART cocktail immunotherapy, which was composed of successive infusions of CART cells targeting epidermal growth factor receptor (EGFR) and CD133, respectively...
January 5, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28056956/effectiveness-of-regionally-specific-immunotherapy-for-the-management-of-canine-atopic-dermatitis
#20
Jon D Plant, Moni B Neradilek
BACKGROUND: Canine atopic dermatitis is a common pruritic skin disease often treated with allergen immunotherapy (AIT). AIT in dogs traditionally begins with attempting to identify clinically relevant environmental allergens. Current allergen testing methodologies and immunotherapy techniques in dogs are not standardized. Immunotherapy with a mixture of allergenic extracts selected based on regional aerobiology rather than intradermal tests or serum IgE assays has been described. The objective of this study was to evaluate the effectiveness of regionally-specific immunotherapy in dogs with atopic dermatitis...
January 5, 2017: BMC Veterinary Research
keyword
keyword
54124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"